chrisvoncsefalvay/vaers-outcomes huggingface dataset:
onset today of redness and swelling and itchiness underneath the injection site.  Warm to the touch.
08/19/2008: Patient given Td intradermally; 08/20/2008: Patient reports red welt at injection site; 08/22/2008: Patient reports big bump at injection site; 08/28/2008; Patient reports a little itching at injection site.
(Lt) arm edematous, erythematous, tender to touch. Large ecchymotic area surrounding injection site.
Pt. given vaccine 7/13/16 and father reports shortly after he developed chills, myalgias, headache, tiredness and fever w/Tmax 102 greater than. Symptoms lasted x 1.5 days.
39 year old female with a history of multiple drug allergies presented to the ER for evaluation of mild tongue swelling and periorbital swelling after receiving Flucelvax seasonal flu vaccine.  Symptoms began around 22 hours after vaccine injection.  Signs and symptoms were felt to represent mild angioedema and a minor allergic reaction to vaccination.   There was no anaphylaxis or anaphylactic shock.  Patient received oral diphenhydramine and oral prednisone in ER and was observed.  Symptoms resolved with treatment and patient was discharged from ER uneventfully on the same day.  I was the ER provider who cared for the patient.  I do not believe this meets mandatory reporting criteria for this vaccine based on VAERS guidelines, however I am reporting based on VAERS website instructions to providers.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 71-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), in right arm, as dose 2, single (Batch/Lot number: unknown) and on 04Apr2022 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 71 years for covid-19 immunisation. The patient had no relevant medical history. No known allergies. No other medical history. There were no concomitant medications. No other medication in 2 weeks.   The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 28Apr2022, outcome "unknown" and all described as "Treatment of COVID-19". The patient was tested positive for Covid on 28Apr2022. Paxlovid was prescribed. She took it for 5 days as recommended (from Apr2022 to 02May2022). Tested negative on 05May2022. On 10May2022, she was tested positive again. Symptoms were mild but she has to quarantine again. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (28Apr2022) Positive; (05May2022) negative; (10May2022) Positive. Therapeutic measures were taken as a result of covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Significant angioedema over facial area.  No chest pain, SOB, wheezing.  Treated with prednisone (20mg) for 3-5 days.
profuse perspiration immed p/inj w/bioject;lasted 20min missed work next day;just felt off track;arm was red & swollen;sort of like flu but not achey;same sx w/giving blood;26FEB97 feeling better-arm sore but OK;rash on chest OK;
Slight swelling and soreness at injection sight. OTC pain reliever. Pain and swelling gone by2/6/2021
30 minute episode of temporary confusion, hallucination followed by headache.  Prior to that only fatigue, myalgia.
This spontaneous report was receive from a Licensed Practical Nurse concerning to an unspecified number of patients of an unknown age and gender. The patients' concurrent conditions, medical history, historical drugs a concomitant medications were not reported. On unknown dates, the patients were vaccinated with improperly stored doses of GARDASIL 9 (lot numbers K011562, expiration date 08-APR-2017; M030380, expiration date 01-FEB-2019, dose, route and anatomical location were not reported) for prophylaxis. The temperature was between 0 Centigrade degrees and 2 Centigrade degrees, the time frame was 33 hours and the previous temperatures excursion were: 4 previous excursions: 1. between 0 Centigrade degrees and 2 Centigrade degrees for 32 hours; 2. between 0 Centigrade degrees and 2 Centigrade degrees for 30 hours; 3. between 0 Centigrade degrees and 2 Centigrade degrees for 29 hours; 4. between 0 Centigrade degrees and 2 Centigrade degrees for 36 hours. These temperature excursions were detected with digital data logger. No adverse effect was reported. A product quality complaint was not involved. Additional information has been requested. This is one of several reports received from the same reporter. Lot number K011562  is not valid for GARDASIL 9. However, it was valid for GARDASIL. Sender's Comments: US-009507513-1701USA008611:Original Case: 1701USA008041; US-009507513-1701USA008041:Original Case : 1701USA008041; US-009507513-1701USA008608:Original Case : 1701USA008041; US-009507513-1701USA008609:Original Case : 1701USA008041.
PATIENT EXPERIENCED REDNESS AND ITCHING AT INJECTION SITE.  PATIENT INFORMED ADMINISTRATOR OF THE VACCINE ADVERSE REACTION ON 11-9-07 (2 DAYS AFTER THE INJECTION.)  DR. WAS INFORMED OF THE REACTION AND SUGGESTED WARM COMPRESS AND BENADRYL. FOLLOW-UP WITH THE PATIENT ON THE 11-11-07, THE PATIENT REPORTED THE REDNESS WAS ALMOST GONE AND NO ITCHING. THE VACCINE ADMINSRATION CONSENT FORM WAS FAXED TO THE DR.
Shingles; Rash / rash on face; This case was reported by a consumer via call center representative and described the occurrence of shingles in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   In July 2019, the patient received the 1st dose of Shingrix. On 3rd September 2019, less than 2 months after receiving Shingrix, the patient experienced shingles and rash. On an unknown date, the outcome of the shingles and rash were not recovered/not resolved.   It was unknown if the reporter considered the shingles and rash to be related to Shingrix.  Additional case details were reported as follows: The age at vaccination was not reported. The patient had first dose of Shingrix about 7 weeks ago.  Last Tuesday patient thought she had a rash on her face, believed to be from antibacterial cleaner she placed on her face while visiting friend in hospital. The reporter's friend referred the patient to see a physician after having seen the rash.  The patient was seen by dermatologist on day of reporting and diagnosed with Shingles. The patient was prescribed three different medications she stated, but names were not provided. It was reported that emergency room visit was required. The reporter consented to follow up. In the XML document outcome of events was reported as recovering, but in system its mentioned as not recovered, so kept as reported in system.
Pt. returned to MD office day after vaccination with pain, swelling and erythema at injection site. Treated with cephalexin 500 mg capsule .
pt felt warm  & was given APAP; 12MN pt screamed & parents heard lots of bed movement; check on  pt, who had thrown up, became lethargic; 215AM pt screamed again; mom found pt w/eye rolling round, & arms shaking-pt collasped;  t102
While administering MMR vaccine patient flinched arm and needle came out a little and some of the medication got into the right eye of the administrator. Patient did not receive the full dose.
Flu vaccine and COVID-19 booster received on the same day, same arm (left). The following day the left side of neck down to the armpit were swollen and tender to touch. There was also bruising on the site of flu injection.
Fatigue, body pain, can?t move left arm due to pain, vomiting, nausea, fever
3  days after vaccination I started to have intermittent localized  "heat" sensation in right side of skull.  It would only last for a short time, a minute or two, maybe a little longer and then disappear. It was an intense heat feeling but with no pain.  I was sitting quietly doing a puzzle. Because of the weekend unable to contact Dr and on call Dr did not respond to my callback request.  Monday 2/15/21 talked to Dr and he it's not a vaccine reaction and it'll go away.   This continued occasionally for a few days until day 5 and 6  the heat sensation increased and duration of event  was much longer, lasting  most of the day with short time spans between episodes. Heat sensation moved from right side of skull to top of head and was very intense, having to use a icepack for some relief.  Called Dr a second time and told me to wait it out and call him next week to report status. By day 7  there is  a mild headache but intensity of the heat sensation in skull has decreased to milder and  less frequent again.  Day 13  symptoms were almost completely resolved but  by  14/15 they have returned though milder than worst symptoms were.  I called Dr's office on Friday 2/19 and they said to call back next week if symptoms do not get better will refer to nruology.
Post vax, this pt complained of the arm being swollen, red and sore. The pt was instructed to use warm, moist soaks and to take Benadryl. The pt reported that "soaks didn't help much but Benadryl helped quite a bit."
Patient started seizing minutes after getting the vaccine which lasted about 30 minutes. Patient  does have a history of seizures and takes medication for them.
Child received DTAP  1, Hep A 1, IPV 1, MMR 1 on 05/03/2004, without immediate side effects. Mother states child left arm was swollen on 5/6/04, took child to children's medical center. Advised not to receive anymore DTAP, HEP A vaccine. Given Keflex 125/5 1 tsp TIDx 10 days and benadryl 12.5/5 1.5 tsp at 6 hr until swelling gone. Mother did not take child back to children's medical center for follow up and did not notify this facility.
Numbness in left hand and arm in C4-5-6 distribution with muscle fasciculations followed by temperature changes on right side of body, ataxia, and lower extremity weakness.  Intermittent severe left-sided muscle cramping.
sore throat is reported in a pt who recvd 1 dose of flu vax; pt recvd flu vax on 4OCT93 & exp the above sx as of 21OCT93; pt recvd flu vax for the last 5 yrs & had exp an occasional h/a;
patients who received a vaccine which was more than 30 days in the refrigerator (30 days were on 03Jul2021); This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patients who received a vaccine which was more than 30 days in the refrigerator (30 days were on 03Jul2021)) in a 47-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Jul-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (patients who received a vaccine which was more than 30 days in the refrigerator (30 days were on 03Jul2021)). On 14-Jul-2021, EXPIRED PRODUCT ADMINISTERED (patients who received a vaccine which was more than 30 days in the refrigerator (30 days were on 03Jul2021)) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided. Treatment information was not provided.
arm pain; redness; itchiness; This is a spontaneous report from a contactable consumer. A female patient of an unspecified age (Age: 70, Unit: Unknown) received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiry date unknown), via an unspecified route of administration on 14Jan2021 at a SINGLE DOSE for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced arm pain, redness and itchiness on Jan2021. The patient wanted to know if she can still receive second vaccine. She asked if these are common side effects and the efficacy after one dose. The outcome of the events was unknown.  Information on the lot/batch number has been requested.
SECONDARY PROBLEM(S):     COVID-19 -  incidental on admission swab.   no respiratory symptoms, on room air - de-isolation date 7/11/2023
chest discomfort; tingling of her body; This spontaneous case was reported by a consumer and describes the occurrence of CHEST DISCOMFORT (chest discomfort) and PARAESTHESIA (tingling of her body) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced CHEST DISCOMFORT (chest discomfort). On an unknown date, the patient experienced PARAESTHESIA (tingling of her body). At the time of the report, CHEST DISCOMFORT (chest discomfort) and PARAESTHESIA (tingling of her body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Approximately one week post vax, pt developed a rash on her trunk.  By the next day the rash had spread over most of her body and she had a fever of 101.2F with chills. The next day pt developed aching joints.
Rash, itchy throat, SOB, itchy eyes, coughing, wheezing, pt felt as if she was burning inside. Started at 3pm 12/16/15. 2 EPI injections 1 BENADRYL injection.
Swelling, erythema, tenderness. Rx: PERIACTIN, PREDNISOLONE.
Already had back pain but starting the day after the shot it was very hard to walk for about 2 days, especially on the stairs. Still limping slightly 2 weeks later. Not sure if its due to the shot or just Age
Fever of about 103, aches, chills, pain in arm.  Lasted 48 hours.
Information has been received from a medical assistant regarding a 14 year old male patient with asthma, SUPRAX allergy and AUGMENTIN allergy. On 31-JUL-1999, the patient was vaccinated with the first dose of (Merck) VARIVAX (dose and route was not provided) (lot number 0300J, expiration date unknown) and on 21-MAY-2007, was vaccinated with the second dose of (Merck) VARIVAX (dose, route, lot number and expiration date were not provided). Concomitant therapies included PROAIR, albuterol, PULMICORT and SINGULAIR. On or around 13-FEB-2013, the patient developed shingles. The patient was treated with VALTREX for the adverse event. Viral culture was performed (result was not provided). The patient sought medical attention, patient presented at the physician's office. The outcome of shingles was unknown. Additional information is not expected.
The nurse gave me shot however did not get in muscle was in subcutaneous area. Left large bruise and swelling and moderate bleeding after shot. My concern is did I get enough of the vaccine in me   Since this was administration error.
Information has been received from a RN concerning a 31 month old female with no past medical history and no known drug allergies who on 14Aug2003 was vaccinated with a dose of varicella virus vaccine live. There was no concomitant medication. On 20Jan04 the pt presented to the physician's office with varicella like lesions on her eyelid. The lesions were treated with an ocular antibiotic to prevent secondary infection. The lesion on the eyelid has since resolved, but the child's mother has reported that more lesions have developed in other places "over the last month". No other information was available. Unspecified medical attention was sought. No lab diagnostic studies were performed. There was no product quality complain. Additional information has been requested.
patient very nearly loss consciousness and fell on the floor; felt worse; malaise; light headed / dizziness; felt pressure in his  chest; weakness; more  fatigue/extreme  fatigue; bradycardia effect / heart rate was 37 / slower heart rate; This spontaneous case was reported by a consumer and describes the occurrence of LOSS OF CONSCIOUSNESS (patient very nearly loss consciousness and fell on the floor) and BRADYCARDIA (bradycardia effect / heart rate was 37 / slower heart rate) in a 53-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included GABAPENTIN and SUMATRIPTAN SUCCINATE (IMITREX [SUMATRIPTAN SUCCINATE]) for Migraine, MELOXICAM for Tennis elbow.   On 01-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-May-2021, the patient experienced BRADYCARDIA (bradycardia effect / heart rate was 37 / slower heart rate) (seriousness criterion medically significant), MALAISE (malaise), DIZZINESS (light headed / dizziness), CHEST DISCOMFORT (felt pressure in his  chest), ASTHENIA (weakness) and FATIGUE (more  fatigue/extreme  fatigue). On 01-Jul-2021, the patient experienced LOSS OF CONSCIOUSNESS (patient very nearly loss consciousness and fell on the floor) (seriousness criteria hospitalization prolonged and medically significant). On an unknown date, the patient experienced FEELING ABNORMAL (felt worse). At the time of the report, LOSS OF CONSCIOUSNESS (patient very nearly loss consciousness and fell on the floor), BRADYCARDIA (bradycardia effect / heart rate was 37 / slower heart rate), FEELING ABNORMAL (felt worse), MALAISE (malaise), DIZZINESS (light headed / dizziness), CHEST DISCOMFORT (felt pressure in his  chest), ASTHENIA (weakness) and FATIGUE (more  fatigue/extreme  fatigue) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-May-2021, Heart rate: 37 37. On 01-Jul-2021, Blood pressure measurement: Abnormal. On 01-Jul-2021, Echocardiogram: dilation and leaky valve Dilation and leaky valve. On 01-Jul-2021, Heart rate: Normal resting heart rate was 62-64, now its 49-50. Patients standing and walking used to be 75-85, now its 58-57 (standing), 60 (walking).    Patient said that over the last two months his sleeping Heart Rate was 42 to 43 and dipped down to 39 sometimes. No treatment drug details was reported.   This case was linked to MOD-2021-253997 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
01/27/22 presents to ED for "N/V and abdominal pain". PMHx of "asthma, depression, Arachnoid cyst s/p craniectomy for fenestration of cyst (11/1/17). Cyclic vomiting syndrome"
Elevated temperature, feeling as though I was outside of my body during fever (quasi-dissociative), sweating and heat episodes (heat feels like it's emanating from from my neck/shoulder area). Additional  SE's: pain at injection site, fatigue.   Quasi-dissociative feeling resolved after fever stopped. At this writing, still having sweating episodes, pain diminished considerably, fatigue waxing and waning.
prevnar on 4/26/18,,,,,,,arm inflamed from injection site distally to elbow.
Patient reported she had pain following the flu shot. She came to the pharmacy on 10/05/2022 and told my technician  that the flu shot was too high up on the shoulder and hit a nerve. I contacted the patient the following day to check on her and the doctor told her that the vaccine may caused the side effect. I called the doctor and spoke to the assistant because the physician was busy and she said that the vaccine might be administered a little wrong per MD but she said that the patient is fine overall during the visit.
22 hours after receiving my second dose of the vaccine, and I have a slightly red, warm lower right arm. I received my vaccine on my left arm, which is NOT red and warm. It is only red and warm at my incision site along my right ulna from a surgery I had a little over a year and a half ago.
dose administered to patient after more than 1 temperature excursion; dose administered to patient after more than 1 temperature excursion/vial stored at cooler storage during high-pace COVID-19 vaccination clinic at the time of the excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (dose administered to patient after more than 1 temperature excursion/vial stored at cooler storage during high-pace COVID-19 vaccination clinic at the time of the excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (dose administered to patient after more than 1 temperature excursion) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021 at 3:22 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 12-Feb-2021 at 3:22 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (dose administered to patient after more than 1 temperature excursion/vial stored at cooler storage during high-pace COVID-19 vaccination clinic at the time of the excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (dose administered to patient after more than 1 temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (dose administered to patient after more than 1 temperature excursion/vial stored at cooler storage during high-pace COVID-19 vaccination clinic at the time of the excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (dose administered to patient after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The vial was initially stored in the fridge on 09-Feb-2021, moved to clinic on 12-Feb-2021 and proposed beyond use date was 10-Mar-2021.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  It was reported that each time a vial was put into a cooler, sometimes there was a period of time of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34 or 35 degree Fahrenheit.  On the date of administration, at 09:00 A.M., the temperature recorded was 29 degree Fahrenheit, at 10:00 A.M., the temperature recorded was 35 degree Fahrenheit and at 11:00 A.M., the temperature recorded was 35 degree Fahrenheit that has been reached by the vial.  Temperature recordings were taken using a traceable temperature monitor at every hour.  The vial was not in a frozen state at the time of vaccine administration.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  No treatment information was provided.   This case was linked to MOD-2022-566976 (Patient Link).
Pt fainted after shot and appeared to have a mild seizure, his face became really red and appeared to stop breathing briefly.  The whole reaction lasted about a minute and when I was about to use an epi pen he came to and assured me he was fine.
First week in March, 2021, started to have significant lymph tenderness in neck that spread to arm left and right pits.  This was a month after second COVID vaccine. Primary care provider ordered ultrasound of neck and arm areas. Also referred to hematologist who requested a biopsy. No significant lymph node swelling so doctor declined to do a biopsy. Tenderness continued for several months and has been most noticeable in the early morning when arising. Sometimes the neck lymph nodes were enlarged. COVID booster received August 30, 2021. One week after COVID booster, neck and arm pit lymph nodes were tender with neck lymph slightly enlarged. Lymph node tenderness continues but to a lesser degree.
2nd Pfizer COVID-19 vaccine on 4/1/2021.  Developed Bell's palsy on 4/11/2021.